文献速递造血干细胞移植与细胞治疗

移植后环磷酰胺与环孢素A联合甲氨蝶呤在同胞全合移植中预防GVHD的比较

Posttransplant cyclophosphamide vs cyclosporin A and methotrexate as GVHD prophylaxis in matched sibling transplantation.
PubMed 文献 · Blood Adv · 2019-01-01

该回顾性研究纳入107例接受HLA同胞全合(10/10)造血干细胞移植的患者,比较移植后环磷酰胺(PTCy)方案与甲氨蝶呤联合环孢素A(MTX-CsA)预防GVHD的效果。PTCy组100天II-IV级和III-IV级急性GVHD累积发生率更低,但2年总生存、无事件生存、复发及非复发死亡率无统计学显著差异;PTCy组GVHD无复发生存(GRFS)更优。

核心结论

  • 在HLA同胞全合移植中,PTCy联合额外免疫抑制方案可降低急性GVHD发生率并改善GRFS,安全性结果与MTX-CsA相当。

研究设计与样本

  • 西班牙2个中心的回顾性研究,纳入107例连续接受HLA同胞全合(10/10)造血干细胞移植的患者。
  • 50例接受MTX-CsA预防GVHD,57例接受PTCy为基础联合额外免疫抑制的方案。
  • 大多数患者(97例,91%)使用未处理的外周血干细胞(PBSC)移植物。

临床怎么用

  • 在HLA同胞全合移植中,可考虑采用PTCy联合额外免疫抑制方案以降低急性GVHD发生率并改善GRFS。
  • 该方案安全性结果与MTX-CsA相当,但需进一步前瞻性研究确认。

局限性

  • 回顾性研究设计,样本量有限(107例),来自2个中心。
  • 大多数患者使用PBSC移植物,结果可能不完全适用于骨髓移植物。
  • 需要进一步前瞻性研究确认这些观察结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Posttransplant cyclophosphamide (PTCy) effectively prevents graft-versus-host disease (GVHD) after HLA-haploidentical hematopoietic stem cell transplantation (HSCT). The use of PTCy in HLA-identical HSCT is less explored. We conducted a retrospective study of 107 consecutive patients undergoing an HLA-identical sibling (10/10) HSCT in 2 centers in Spain, 50 with GVHD prophylaxis with methotrexate-cyclosporin A (MTX-CsA) and 57 using a PTCy-based regimen with additional immunosuppression. Graft source was unmanipulated mobilized peripheral blood stem cells (PBSC) in most patients (97 patients, 91%). Cumulative incidences of grade II to IV and III to IV acute GVHD at 100 days were lower in the PTCy group (22.6% vs 52.2%, P = .0015; 8.8% vs 24.4%, P = .016), without statistically significant differences in the 2-year cumulative incidence of chronic moderate to severe GVHD (16.7% vs 26%, P = .306). At 2 years, no statistically significant differences were observed in OS (78% vs 56%, P = .088), EFS (62.5% vs 48%, P = .054), relapse (28% vs 27%, P = .47), and NRM (8.8% vs 24%, P = .054). The composite endpoint of GVHD and relapse-free survival (GRFS) was favorable for the PTCy group (24% vs 48%, P = .011), PTCy being the sole independent factor identified in the multivariate analysis for this endpoint. In this study, PTCy combination with additional immunosuppression using mostly PBSCs grafts showed a reduction of acute GVHD rate and an impact on GRFS, with safety results comparable with those obtained with MTX-CsA. Further prospective studies are needed to confirm these observations..

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Kwon M, Bailén R, Pascual-Cascón MJ, et al. Posttransplant cyclophosphamide vs cyclosporin A and methotrexate as GVHD prophylaxis in matched sibling transplantation. Blood Adv. 2019. PMID: 31698447. doi:10.1182/bloodadvances.2019000236

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。